To do this, they primarily decrease tumor-retarding IFNγ+ CD4+ T cells in the tumor31, presumably by utilizing the B-MF-expressed immunoregulatory factors, TGFβ/LAP and PD-L125,26, and LDLR. The gene discussed is CD4; the disease is neoplasm.